Asia Deal Watch: BeiGene And Celgene Exit Their Anti-PD-1 Collaboration
Executive Summary
The Chinese firm regains all rights to tislelizumab ahead of the closing of Celgene’s merger with Bristol-Myers Squibb. BeiGene also forms cancer JV with US biotech SpringWorks.
You may also be interested in...
FDA Approval Makes Deciphera’s Qinlock First Fourth-Line GIST Drug
Qinlock (ripretinib), approved as the US FDA rejected Blueprint Medicines’ Ayvakit (avapritinib) in the same indication, is priced on par with the rival drug cleared in January for a narrower GIST use.
Deciphera Plans Ripretinib NDA Filing For Q1 2020 On Phase III GIST Data
CEO Steve Hoerter sees best-in-class potential for the drug based on both efficacy and safety in the fourth-line gastrointestinal stromal tumor setting, with the INVICTUS trial having positive readthrough to the ongoing Phase III INTRIGUE study in second-line GIST.
Asia Executives On The Move: BMS Names New China GM, New President For Nippon Kayaku
The coming of summer has seen a flurry of executive changes in the Asia Pacific biopharma sector. BMS has named a new China GM amid a fierce immuno-oncology battle, Parexel Japan has a new president, and other personnel changes take place at Nippon Kayaku, Zai Lab and Harbour BioMed.